As you know, high-risk patients with MDS are treated normally by different means. First of all, allogeneic bone marrow transplant for some patients, high-risk patients, and others are treated by hypomethylated agents like azacitidine and decitabine. So in our study, we have included 30 patients with high-risk MDS, myelodysplastic syndrome. Those patients fall into the high-risk category in the classification revised and original classification of International Prognostic Index for MDS...
As you know, high-risk patients with MDS are treated normally by different means. First of all, allogeneic bone marrow transplant for some patients, high-risk patients, and others are treated by hypomethylated agents like azacitidine and decitabine. So in our study, we have included 30 patients with high-risk MDS, myelodysplastic syndrome. Those patients fall into the high-risk category in the classification revised and original classification of International Prognostic Index for MDS. So we have given this kind of patients high-dose chemotherapy composed of cytarabine at the dose of three grams every week for eight consecutive weeks, and azacitidine at the dose of 75 milligrams per day for five consecutive days every month and continuous until disease progression and the low dose of lenalidomide as immunomodulator at a dose of 10 milligrams per day in continuous disease progression. So we have evaluated our patients by bone marrow aspiration every four weeks and we have found that the majority of our patients are in good response, I mean partial and complete response. So we had 25% of patients in complete response after the end of cytarabine and after three months after the first block of azacitidine and lenalidomide, we have demonstrated a complete response in 40% of cases. However, patients failed to get a good response, moved to another treatment, including allogeneic bone marrow transplant. And after two years of follow-up, the progression-free survival was around 40% and the overall survival rate was between 60 to 65% according to the treatment given after progression.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
